Mycoplasma Genitalium Infection and Associated Antimicrobial Resistance Among HIV-infected Male in Hong Kong
Launched by CHINESE UNIVERSITY OF HONG KONG · Mar 16, 2023
Trial Information
Current as of June 12, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying Mycoplasma genitalium (MG), a type of bacterial infection that can be transmitted through sexual contact. Researchers want to find out how common MG infections are among men living with HIV in Hong Kong and whether these infections are resistant to certain antibiotics, which are used to treat them. The study will involve about 750 HIV-infected men who visit a specialized clinic, and it will also look for any other sexually transmitted infections that might be present at the same time.
To participate in the trial, men must be 18 years or older, HIV-infected, and able to communicate in English or Chinese. They should also be willing to provide consent to take part in the study. Participants can expect to undergo tests to check for MG and other infections, and their experiences will help improve our understanding of these health issues in a community that may be at higher risk. It's important to know that this study is currently recruiting participants and aims to contribute valuable information about managing sexually transmitted infections in HIV-infected individuals.
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • aged 18 or older, male, HIV-infected, and are attendees of the HIV specialist clinic, and can communicate in written and spoken English or Chinese
- Exclusion Criteria:
- • not able to provide consent
About Chinese University Of Hong Kong
The Chinese University of Hong Kong (CUHK) is a prestigious research institution renowned for its commitment to advancing medical science and improving healthcare outcomes. As a clinical trial sponsor, CUHK leverages its extensive academic resources and interdisciplinary expertise to conduct innovative research that addresses critical health challenges. The university fosters collaboration among leading researchers, healthcare professionals, and industry partners, ensuring rigorous study design and implementation. CUHK is dedicated to upholding the highest ethical standards in clinical research, with a focus on translating findings into tangible benefits for patients and the broader community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, Hong Kong, China, Hong Kong
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials